Full text
Earnings transcript
Read the complete earnings call transcript.
MYGN
Myriad Genetics, Inc.
$4.75
0.16
(3.49%)
[ms_data_label text=’Delayed data’]
| Exchange: | NASDAQ |
| Market Cap: | 444.164M |
| Shares Outstanding: | 30.256M |
About The Company
| Sector: | Healthcare | |||||
| Industry: | Medical – Diagnostics & Research | |||||
| CEO: | Samraat S. Raha | |||||
| Full Time Employees: | 2700 | |||||
| Address: |
| |||||
| Website: | https://myriad.com |
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women’s and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. In addition, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics for an offering of germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 753,200 | 837,600 | 824,500 |
| Gross Profit | 517,000 | 585,400 | 576,600 |
| EBITDA | -197,400 | -59,500 | -397,400 |
| Operating Income | -257,400 | -123,500 | -139,300 |
| Net Income | -263,300 | -127,300 | -365,900 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 1,146,500 | 1,027,600 | 706,600 |
| Total Liabilities | 363,300 | 326,500 | 338,600 |
| Total Stockholders Equity | 783,200 | 701,100 | 368,000 |
| Total Debt | 152,100 | 140,300 | 209,800 |
| Cash and Cash Equivalents | 132,100 | 102,400 | 149,600 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | -110,900 | -8,700 | 1,800 |
| Capital Expenditure | -73,300 | -29,700 | 0 |
| Free Cash Flow | -184,200 | -38,400 | 1,800 |
| Net Income | -263,300 | -127,300 | 0 |
| Net Change in Cash | 74,500 | -29,000 | 39,400 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Full Access | Full Access | Full Access | Full Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 1,033,618.744 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (High) | 1,054,405.059 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (Avg) | 1,043,189.900 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Low) | -194,463.747 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (High) | -190,630.130 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Avg) | -192,395.337 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Low) | 57,031.491 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (High) | 58,527.090 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Avg) | 57,720.045 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Low) | 748,064.991 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (High) | 763,108.754 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Avg) | 754,991.962 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Avg) | 0.620 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (High) | 0.630 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Low) | 0.610 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated Revenue) | 3 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated EPS) | 1 | Full Access | Full Access | Full Access | Full Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
At what price to buy it? -
Intrinsic Value Calculator
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
Common questions about MYGN valuation
Is Myriad Genetics, Inc. (MYGN) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for Myriad Genetics, Inc. (MYGN) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is MYGN a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether MYGN trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is MYGN’s P/E ratio?
You can see MYGN’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for MYGN?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is MYGN a good long-term investment?
Whether MYGN fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
MYGN
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
[ms_data_label text="Daily snapshot"]
3.49
Trading Metrics:
| Open: | [ms_cell_or_dash table='trading_quote' column='open'] | Previous Close: | [ms_cell_or_dash table='trading_quote' column='previousClose'] | |
| Day Low: | [ms_cell_or_dash table='trading_quote' column='dayLow'] | Day High: | [ms_cell_or_dash table='trading_quote' column='dayHigh'] | |
| Year Low: | 3.76 | Year High: | 8.63 | |
| Price Avg 50: | 4.92 | Price Avg 200: | 6.09 | |
| Volume: | 1.121M | Average Volume: | 1.705M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's free
